H.C. Wainwright analyst Swayampakula Ramakanth upgraded VBL Therapeutics to Buy with an unchanged price target of $3. The "unwarranted" valuation decline and clinical readout in 2019 bring "new opportunity," Ramakanth tells investors in a research note. The stock has fallen 46% since March 3 despite no negative news from the company, the analyst says. He believes VBL's "promising" pipeline developments over the last six months, the weakness in the stock price, and the major clinical readout expected in 2019 has "significantly increased" the company's value proposition.